Hope springs eternal: The importance of planning, serendipity and vision in clinical trial outcomes

IDrugs

Volumn 1, Issue 8, 1998, Pages 887-889

  Williams, Michael ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001759545     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Thompson WL: Research investments in a managed-core, cost-containment oligopsony. Ann Rep Med Chem (1995) 30:339-345.
2. 4 dopamine antagonist group: The effects of a selective D4 dopamine receptor antagonist (L745.870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiat (1997) 54:567-572.
3. Zipkin I: Fourth time lucky? BioCentury: The Bernstein Report on BioBusiness (1998) July 13: pp A6-A7.
4. Hooper MB, Amsterdam JD: Do clinical trials reflect drug potential? A review of 5 FDA evaluations of new antidepressants. NIJ New Drug Clinical Evaluation Unit (NDCEU) Annual Meeting (1998): Poster 182.
5. Kleyn PW, Vessell ES: Genetic variation as a guide to drug development. Science (1998) 281:1820-1821.
6. Kramer MS, Cutler N, Feighner J, Shrivasatava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicci GG, Sadowaksi S, Williams AR, Hewson L, Smith D, Cartson EJ, Hargreaves RJ, Rupniak NMJ: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640-1645.
7. Mantyh PW, Allen CJ, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE: Rapid endocytosis of G protein-coupled receptor: substance P-evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA (1995) 92:2622-2626.
8. Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM: LY 303970, a centrally active neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther (1998) 280:774-785.
9. Goldstein D: Clinical trials with lanepitant. In Tachykinins and their Antagonists. William Harvey Conferences, London (1996):28.
10. Iversen L: Substance P equals pain substance? Nature (1998) 392:334-335.
11. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJH, Laird JMA, Belmomte C, Cervero F, Hunt SP: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature (1998) 392:394-397.
12. Coyle JT, Price DL, Delong MR: Alzheimer's disease: a disorder of cholinergic innervation. Science (1983) 219:1184-1190.
13. Bonner TI, Buckley NJ, Young AC, Brann MR: Identification of a family of muscarinic acetylcholine receptor genes. Science (1987) 237:527-532.
14. Williams M, Davis RE: Alzheimer's disease and related dementias: prospects for treatment. Exp Opin Invest Drugs (1997) 6:735-757.
15. Scrip (1998) 2364:16.